Alterity Therapeutics (ATHE) Institutional Ownership $4.70 -0.19 (-3.79%) Closing price 03:58 PM EasternExtended Trading$4.72 +0.02 (+0.43%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Alterity Therapeutics (NASDAQ:ATHE)CurrentInstitutional OwnershipPercentage2.14%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$252.42KNumber ofInstitutional Sellers(last 12 months)0 Get ATHE Insider Trade Alerts Want to know when executives and insiders are buying or selling Alterity Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ATHE Institutional Buying and Selling by Quarter Alterity Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/17/2025 Greenleaf Trust17,000$70K0.0%N/A0.192% 5/7/2025HB Wealth Management LLC37,483$129K0.0%+17.6%0.423% 2/17/2025Point72 Asset Management L.P.32,627$108K0.0%N/A0.373% 2/17/2025BNP Paribas Financial Markets8,790$29K0.0%N/A0.101% 1/15/2025HB Wealth Management LLC31,883$110K0.0%+34.1%0.436% 2/4/2022Envestnet Asset Management Inc.82,386$59K0.0%N/A0.364% 8/13/2021Renaissance Technologies LLC237,903$309K0.0%+5.9%1.052% (Data available from 1/1/2016 forward) ATHE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ATHE shares? During the previous two years, the following institutional investors and hedge funds held shares of Alterity Therapeutics shares: HB Wealth Management LLC ($129K), Point72 Asset Management L.P. ($108K), and Greenleaf Trust ($70K), BNP Paribas Financial Markets ($29K).Learn more on Alterity Therapeutics' institutional investors. What percentage of Alterity Therapeutics' stock is owned by institutional investors? 2.14% of Alterity Therapeutics' stock is owned by institutional investors. Learn more on ATHE's institutional investor holdings. Which institutional investors have been buying Alterity Therapeutics' stock? The following institutional investors have purchased Alterity Therapeutics' stock in the last 24 months: Point72 Asset Management L.P. ($32.63K), Greenleaf Trust ($17K), HB Wealth Management LLC ($13.70K), and BNP Paribas Financial Markets ($8.79K). How much institutional buying is happening at Alterity Therapeutics? Institutional investors have bought a total of 72,117 shares in the last 24 months. This purchase volume represents approximately $252.42K in transactions. Related Companies VTYX Institutional Ownership MDWD Institutional Ownership FTLF Institutional Ownership CRBU Institutional Ownership BTMD Institutional Ownership ACTU Institutional Ownership BIOA Institutional Ownership TVGN Institutional Ownership KYTX Institutional Ownership NVCT Institutional Ownership This page (NASDAQ:ATHE) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
